Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2016

View Archived Issues

Evotec and Inserm establish oncology research collaboration

Zhejiang DTRM Biopharma initiates phase I trial of DTRMWXHS-12

Charles River enters partnership agreement with Tri-I TDI

FDA grants orphan drug designation to BIIB-067 for the treatment of ALS

Grant supports collaborative research into uveal melanoma

UC Riverside to evaluate ecopipam for the treatment of stuttering

Allele receives NIH Grant to develop a new antibody therapy for Alzheimer's disease

Asit Biotech to start a phase IIa trial of Hdm-Asit

Immunotoxin D2C7-(scdsFv)-PE38 KDEL receives FDA orphan status for glioma

Aurigene Discovery Technologies patents PD-1 signaling inhibitors

Merck & Co. discloses IRAK-4 inhibitors

Peloton Therapeutics describes HIF-2alpha inhibitors

Janssen Biotech submits BLA to the FDA for sirukumab

Bristol-Myers Squibb develops ROCK2 inhibitors

FDA approves adalimumab biosimilar Amjevita

Fate Therapeutics' ProTmune receives orphan drug designation

FDA accepts for priority review dupilumab BLA for atopic dermatitis

FDA grants expanded use approvals for Novartis' canakinumab

Ligand licenses programs to Seelos Therapeutics

FDA approves Rexulti labeling update for maintenance treatment of schizophrenia

MELK inhibition overcomes drug resistance in myeloma cell lines

Neuregulin 1 is a potential novel therapeutic target for the treatment of Alzheimer's disease

Enrollment open in Chugai's phase I trial of ERY-974 for advanced solid tumors

Peptide-mediated oligonucleotide therapy to enter clinical development for spinal muscular atrophy

FDA grants orphan drug designation to modafinil/flecainide fixed dose combination

SK Life Science initiates phase III trial of YKP-3089 for partial onset seizures

Therapy with HDAC6 inhibitor rocilinostat shows promising activity in multiple myeloma trial

Dysferin gene therapy given US orphan status for limb girdle muscular dystrophy type 2B

RO-4993850 attenuates social deficits in schizophrenia model

Reduced soluble CD93 levels linked to type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...